It is expected that CKD Bio and Cell Biotech will compete to expand the related market in the microbiome drug CDMO (Contract Development Manufacturing) field. According to the Korea Institute of Science and Technology Information, the global market for human microbiome is expected to reach 1,743.8 billion won in 2029 with a rapid average annual growth rate of 31% from the current 343.4 billion.

The size of the domestic market is expected to grow from 8 billion won last year to 48 percent annually, reaching 25.9 billion won in 2029. Chong Kun Dang Bio was the first to identify the blue ocean potential and set out to preoccupy the market. CKD Bio continues to invest in clinical trials and commercializatio